Hester Biosciences Share Price
2329.90+0.00 (-0.94%)
+39.36% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
HESTERBIONSE
Hester Biosciences Share Price
2329.90+0.00 (-0.94%)
+39.36% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 13% | 9% | 8% | 7% |
| 11% | 10% | 28% | 99% |
| 13% | 0% | 15% | 39% |
| 16% | 12% | 11% | 17% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
HESTERBIO
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
| 2,350.9 | ₹1996 Cr | 14.05 | 23.94 | 195.79 | ₹56 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹98 Cr | ₹77 Cr | ₹100 Cr | ₹77 Cr | ₹71 Cr | ₹84 Cr | ₹82 Cr | ₹63 Cr | ₹84 Cr | ₹82 Cr | ₹79 Cr | ₹67 Cr | ₹70 Cr | ₹88 Cr | ₹67 Cr | ₹75 Cr | ₹73 Cr | ₹51 Cr | ₹56 Cr | ₹56 Cr | ₹63 Cr | ₹60 Cr | ₹64 Cr | ₹57 Cr | ₹53 Cr | ₹40 Cr | ₹44 Cr | ₹51 Cr | ₹44 Cr | ₹45 Cr | ₹52 Cr | ₹46 Cr | ₹43 Cr | ₹40 Cr |
| ₹2 Cr | ₹2 Cr | -₹3 Cr | ₹67 L | ₹10 Cr | ₹2 Cr | -₹7 Cr | ₹8 Cr | ₹2 Cr | ₹1 Cr | ₹4 Cr | ₹99 L | ₹4 Cr | ₹1 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹7 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹24 L | ₹69 L | ₹5 Cr | ₹30 L | ₹70 L | ₹58 L | ₹6 Cr | ₹27 L | ₹48 L | ₹72 L |
| ₹99 Cr | ₹79 Cr | ₹97 Cr | ₹78 Cr | ₹81 Cr | ₹86 Cr | ₹75 Cr | ₹71 Cr | ₹86 Cr | ₹83 Cr | ₹83 Cr | ₹68 Cr | ₹75 Cr | ₹89 Cr | ₹70 Cr | ₹79 Cr | ₹78 Cr | ₹54 Cr | ₹64 Cr | ₹58 Cr | ₹64 Cr | ₹63 Cr | ₹67 Cr | ₹58 Cr | ₹54 Cr | ₹41 Cr | ₹48 Cr | ₹51 Cr | ₹45 Cr | ₹45 Cr | ₹58 Cr | ₹46 Cr | ₹43 Cr | ₹41 Cr |
| ₹72 Cr | ₹62 Cr | ₹72 Cr | ₹64 Cr | ₹64 Cr | ₹65 Cr | ₹67 Cr | ₹62 Cr | ₹69 Cr | ₹69 Cr | ₹67 Cr | ₹61 Cr | ₹62 Cr | ₹79 Cr | ₹61 Cr | ₹61 Cr | ₹65 Cr | ₹48 Cr | ₹51 Cr | ₹46 Cr | ₹48 Cr | ₹46 Cr | ₹48 Cr | ₹39 Cr | ₹41 Cr | ₹31 Cr | ₹40 Cr | ₹33 Cr | ₹36 Cr | ₹30 Cr | ₹39 Cr | ₹28 Cr | ₹31 Cr | ₹27 Cr |
| ₹34 Cr | ₹24 Cr | ₹31 Cr | ₹18 Cr | ₹21 Cr | ₹25 Cr | ₹12 Cr | ₹13 Cr | ₹21 Cr | ₹19 Cr | ₹20 Cr | ₹11 Cr | ₹18 Cr | ₹16 Cr | ₹15 Cr | ₹23 Cr | ₹17 Cr | ₹11 Cr | ₹18 Cr | ₹18 Cr | ₹19 Cr | ₹19 Cr | ₹22 Cr | ₹22 Cr | ₹16 Cr | ₹13 Cr | ₹12 Cr | ₹21 Cr | ₹12 Cr | ₹18 Cr | ₹23 Cr | ₹20 Cr | ₹16 Cr | ₹16 Cr |
| ₹3 Cr | ₹3 Cr | ₹5 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹6 Cr | -₹4 Cr | ₹6 Cr | ₹5 Cr | ₹7 Cr | ₹2 Cr | ₹8 Cr | ₹3 Cr | ₹1 Cr | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹96 L | ₹74 L | ₹86 L | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr |
| ₹25 Cr | ₹100 Cr | ₹23 Cr | ₹12 Cr | ₹15 Cr | ₹19 Cr | ₹2 Cr | ₹12 Cr | ₹11 Cr | ₹10 Cr | ₹9 Cr | ₹5 Cr | ₹5 Cr | ₹8 Cr | ₹8 Cr | ₹14 Cr | ₹10 Cr | ₹4 Cr | ₹11 Cr | ₹12 Cr | ₹15 Cr | ₹15 Cr | ₹14 Cr | ₹18 Cr | ₹11 Cr | ₹8 Cr | ₹6 Cr | ₹15 Cr | ₹7 Cr | ₹13 Cr | ₹17 Cr | ₹17 Cr | ₹10 Cr | ₹12 Cr |
| ₹19 Cr | ₹95 Cr | ₹15 Cr | ₹8 Cr | ₹12 Cr | ₹16 Cr | ₹23 L | ₹10 Cr | ₹7 Cr | ₹7 Cr | ₹6 Cr | ₹3 Cr | ₹2 Cr | ₹5 Cr | ₹5 Cr | ₹10 Cr | ₹6 Cr | ₹2 Cr | ₹9 Cr | ₹8 Cr | ₹11 Cr | ₹11 Cr | ₹10 Cr | ₹13 Cr | ₹7 Cr | ₹5 Cr | ₹5 Cr | ₹12 Cr | ₹6 Cr | ₹8 Cr | ₹14 Cr | ₹12 Cr | ₹6 Cr | ₹8 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹6 Cr | ₹5 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 Cr |
| ₹352 Cr | ₹306 Cr | ₹283 Cr | ₹271 Cr | ₹251 Cr | ₹220 Cr | ₹193 Cr | ₹169 Cr | ₹132 Cr | ₹113 Cr | ₹93 Cr | ₹76 Cr | ₹67 Cr | ₹59 Cr | ₹54 Cr | ₹41 Cr |
| ₹352 Cr | ₹306 Cr | ₹283 Cr | ₹271 Cr | ₹251 Cr | ₹220 Cr | ₹193 Cr | ₹169 Cr | ₹132 Cr | ₹113 Cr | ₹93 Cr | ₹76 Cr | ₹67 Cr | ₹59 Cr | ₹54 Cr | ₹41 Cr |
| ₹360 Cr | ₹314 Cr | ₹292 Cr | ₹280 Cr | ₹260 Cr | ₹228 Cr | ₹201 Cr | ₹177 Cr | ₹141 Cr | ₹122 Cr | ₹102 Cr | ₹85 Cr | ₹75 Cr | ₹67 Cr | ₹60 Cr | ₹48 Cr |
| ₹8 Cr | ₹12 Cr | ₹11 Cr | ₹9 Cr | ₹7 Cr | ₹8 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹64 L |
| ₹90 Cr | ₹133 Cr | ₹182 Cr | ₹185 Cr | ₹165 Cr | ₹83 Cr | ₹76 Cr | ₹58 Cr | ₹37 Cr | ₹45 Cr | ₹33 Cr | ₹31 Cr | ₹15 Cr | ₹14 Cr | ₹1 Cr | ₹4 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹90 L | ₹76 L | ₹0 | ₹0 | ₹0 |
| ₹9 Cr | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹9 Cr | ₹11 Cr | ₹8 Cr | ₹4 Cr | ₹8 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr |
| ₹57 Cr | ₹59 Cr | ₹62 Cr | ₹39 Cr | ₹26 Cr | ₹24 Cr | ₹11 Cr | ₹62 L | ₹5 L | ₹15 L | ₹15 L | ₹54 L | ₹1 L | ₹0 | ₹2 Cr | ₹0 |
| ₹2 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹158 Cr | ₹202 Cr | ₹254 Cr | ₹233 Cr | ₹198 Cr | ₹114 Cr | ₹97 Cr | ₹70 Cr | ₹44 Cr | ₹48 Cr | ₹41 Cr | ₹38 Cr | ₹20 Cr | ₹16 Cr | ₹6 Cr | ₹6 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹25 Cr | ₹29 Cr | ₹26 Cr | ₹30 Cr | ₹18 Cr | ₹28 Cr | ₹20 Cr | ₹9 Cr | ₹8 Cr | ₹7 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹3 Cr |
| ₹97 Cr | ₹61 Cr | ₹45 Cr | ₹56 Cr | ₹43 Cr | ₹23 Cr | ₹30 Cr | ₹17 Cr | ₹20 Cr | ₹11 Cr | ₹9 Cr | ₹6 Cr | ₹7 Cr | ₹9 Cr | ₹4 Cr | ₹5 Cr |
| ₹24 Cr | ₹30 Cr | ₹31 Cr | ₹59 Cr | ₹35 Cr | ₹3 Cr | ₹33 Cr | ₹22 Cr | ₹25 Cr | ₹18 Cr | ₹21 Cr | ₹20 Cr | ₹30 Cr | ₹16 Cr | ₹13 Cr | ₹15 Cr |
| ₹7 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹1 Cr | ₹7 Cr | ₹46 L | ₹26 L | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹4 Cr | ₹4 Cr | ₹8 Cr | ₹7 Cr | ₹5 Cr |
| ₹152 Cr | ₹125 Cr | ₹105 Cr | ₹149 Cr | ₹97 Cr | ₹61 Cr | ₹83 Cr | ₹49 Cr | ₹55 Cr | ₹38 Cr | ₹38 Cr | ₹35 Cr | ₹45 Cr | ₹39 Cr | ₹28 Cr | ₹28 Cr |
| ₹678 Cr | ₹653 Cr | ₹662 Cr | ₹670 Cr | ₹562 Cr | ₹411 Cr | ₹387 Cr | ₹299 Cr | ₹244 Cr | ₹213 Cr | ₹186 Cr | ₹160 Cr | ₹142 Cr | ₹124 Cr | ₹95 Cr | ₹82 Cr |
| ₹0 | ₹0 | ₹0 | ₹20 L | ₹15 L | ₹15 L | ₹11 L | ₹11 L | ₹67 L | ₹62 L | ₹62 L | ₹56 L | ₹0 | ₹12 Cr | ₹3 Cr | ₹19 L |
| ₹188 Cr | ₹208 Cr | ₹239 Cr | ₹268 Cr | ₹223 Cr | ₹105 Cr | ₹121 Cr | ₹90 Cr | ₹69 Cr | ₹66 Cr | ₹59 Cr | ₹55 Cr | ₹48 Cr | ₹32 Cr | ₹16 Cr | ₹21 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹585 Cr | ₹390 Cr | ₹382 Cr | ₹386 Cr | ₹348 Cr | ₹228 Cr | ₹226 Cr | ₹216 Cr | ₹170 Cr | ₹153 Cr | ₹108 Cr | ₹98 Cr | ₹87 Cr | ₹65 Cr | ₹62 Cr | ₹58 Cr |
| ₹174 Cr | ₹157 Cr | ₹142 Cr | ₹126 Cr | ₹111 Cr | ₹95 Cr | ₹83 Cr | ₹71 Cr | ₹60 Cr | ₹50 Cr | ₹44 Cr | ₹38 Cr | ₹33 Cr | ₹28 Cr | ₹23 Cr | ₹19 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹14 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹411 Cr | ₹233 Cr | ₹240 Cr | ₹259 Cr | ₹237 Cr | ₹133 Cr | ₹143 Cr | ₹145 Cr | ₹110 Cr | ₹103 Cr | ₹65 Cr | ₹60 Cr | ₹54 Cr | ₹38 Cr | ₹39 Cr | ₹39 Cr |
| ₹0 | ₹177 Cr | ₹168 Cr | ₹146 Cr | ₹80 Cr | ₹109 Cr | ₹74 Cr | ₹7 Cr | ₹32 Cr | ₹21 Cr | ₹36 Cr | ₹33 Cr | ₹21 Cr | ₹29 Cr | ₹6 Cr | ₹4 L |
| ₹43 Cr | ₹34 Cr | ₹30 Cr | ₹25 Cr | ₹21 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹7 L | ₹28 L | ₹28 L | ₹28 L | ₹0 | ₹0 |
| ₹43 Cr | ₹34 Cr | ₹30 Cr | ₹25 Cr | ₹21 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹7 L | ₹28 L | ₹28 L | ₹28 L | ₹0 | ₹0 |
| ₹6 Cr | ₹7 Cr | ₹6 Cr | ₹8 Cr | ₹24 Cr | ₹5 Cr | ₹7 Cr | ₹4 Cr | ₹3 Cr | ₹9 Cr | ₹10 Cr | ₹8 Cr | ₹10 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr |
| ₹49 L | ₹2 Cr | ₹74 L | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr | ₹8 L | ₹47 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹469 Cr | ₹458 Cr | ₹448 Cr | ₹442 Cr | ₹367 Cr | ₹250 Cr | ₹227 Cr | ₹158 Cr | ₹146 Cr | ₹133 Cr | ₹112 Cr | ₹100 Cr | ₹85 Cr | ₹74 Cr | ₹49 Cr | ₹44 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹73 Cr | ₹70 Cr | ₹76 Cr | ₹85 Cr | ₹75 Cr | ₹62 Cr | ₹64 Cr | ₹51 Cr | ₹40 Cr | ₹33 Cr | ₹34 Cr | ₹29 Cr | ₹36 Cr | ₹31 Cr | ₹28 Cr | ₹23 Cr |
| ₹95 Cr | ₹73 Cr | ₹79 Cr | ₹80 Cr | ₹55 Cr | ₹49 Cr | ₹58 Cr | ₹33 Cr | ₹32 Cr | ₹27 Cr | ₹26 Cr | ₹18 Cr | ₹14 Cr | ₹15 Cr | ₹14 Cr | ₹13 Cr |
| ₹7 Cr | ₹7 Cr | ₹15 Cr | ₹15 Cr | ₹25 Cr | ₹21 Cr | ₹24 Cr | ₹41 Cr | ₹13 Cr | ₹11 Cr | ₹5 Cr | ₹7 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹2 Cr |
| ₹7 Cr | ₹8 Cr | ₹6 Cr | ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹3 Cr | ₹7 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹27 Cr | ₹37 Cr | ₹39 Cr | ₹42 Cr | ₹34 Cr | ₹26 Cr | ₹8 Cr | ₹11 Cr | ₹9 Cr | ₹5 Cr | ₹2 Cr | ₹7 Cr | ₹3 Cr | ₹1 Cr | ₹50 L | ₹70 L |
| ₹209 Cr | ₹195 Cr | ₹215 Cr | ₹228 Cr | ₹195 Cr | ₹162 Cr | ₹159 Cr | ₹142 Cr | ₹98 Cr | ₹80 Cr | ₹74 Cr | ₹60 Cr | ₹57 Cr | ₹50 Cr | ₹46 Cr | ₹38 Cr |
| ₹56 Cr | ₹70 Cr | ₹109 Cr | ₹79 Cr | ₹98 Cr | ₹100 Cr | ₹76 Cr | ₹93 Cr | ₹44 Cr | ₹42 Cr | ₹36 Cr | ₹25 Cr | ₹12 Cr | ₹11 Cr | ₹18 Cr | ₹10 Cr |
| ₹678 Cr | ₹653 Cr | ₹662 Cr | ₹670 Cr | ₹562 Cr | ₹411 Cr | ₹387 Cr | ₹299 Cr | ₹244 Cr | ₹213 Cr | ₹186 Cr | ₹160 Cr | ₹142 Cr | ₹124 Cr | ₹95 Cr | ₹82 Cr |
| ₹423 | ₹369 | ₹343 | ₹329 | ₹306 | ₹268 | ₹236 | ₹209 | ₹165 | ₹143 | ₹120 | ₹100 | ₹88 | ₹79 | ₹105 | ₹89 |
| ₹423 | ₹369 | ₹343 | ₹329 | ₹306 | ₹268 | ₹236 | ₹209 | ₹165 | ₹143 | ₹120 | ₹100 | ₹88 | ₹79 | ₹70 | ₹59 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹76 Cr | ₹40 Cr | ₹32 Cr | ₹40 Cr | ₹54 Cr | ₹50 Cr | ₹41 Cr | ₹57 Cr | ₹36 Cr | ₹31 Cr | ₹25 Cr | ₹18 Cr | ₹13 Cr | ₹14 Cr | ₹12 Cr | ₹11 Cr |
| ₹34 Cr | ₹26 Cr | ₹24 Cr | ₹12 Cr | ₹11 Cr | ₹20 Cr | ₹20 Cr | ₹18 Cr | ₹14 Cr | ₹11 Cr | ₹9 Cr | ₹7 Cr | ₹12 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr |
| -₹31 Cr | ₹10 Cr | ₹4 Cr | -₹21 Cr | -₹39 Cr | ₹2 Cr | -₹14 Cr | -₹12 Cr | -₹2 Cr | ₹11 L | -₹9 Cr | -₹33 L | -₹6 Cr | -₹5 Cr | -₹4 Cr | -₹10 Cr |
| ₹78 Cr | ₹76 Cr | ₹60 Cr | ₹32 Cr | ₹26 Cr | ₹72 Cr | ₹48 Cr | ₹63 Cr | ₹47 Cr | ₹42 Cr | ₹25 Cr | ₹25 Cr | ₹19 Cr | ₹17 Cr | ₹15 Cr | ₹8 Cr |
| ₹64 Cr | ₹65 Cr | ₹48 Cr | ₹24 Cr | ₹9 Cr | ₹58 Cr | ₹37 Cr | ₹47 Cr | ₹38 Cr | ₹35 Cr | ₹19 Cr | ₹20 Cr | ₹9 Cr | ₹12 Cr | ₹14 Cr | ₹5 Cr |
| -₹3 Cr | -₹19 Cr | -₹23 Cr | -₹77 Cr | -₹117 Cr | -₹38 Cr | -₹74 Cr | -₹22 Cr | -₹26 Cr | -₹30 Cr | -₹13 Cr | -₹21 Cr | -₹15 Cr | -₹23 Cr | -₹10 Cr | -₹4 Cr |
| -₹49 Cr | -₹52 Cr | -₹26 Cr | ₹42 Cr | ₹112 Cr | -₹18 Cr | ₹19 Cr | ₹3 Cr | -₹11 Cr | ₹2 Cr | -₹7 Cr | ₹7 Cr | ₹7 Cr | ₹10 Cr | -₹2 Cr | -₹81 L |
| ₹12 Cr | -₹6 Cr | -₹52 L | -₹12 Cr | ₹4 Cr | ₹1 Cr | -₹19 Cr | ₹28 Cr | ₹1 Cr | ₹6 Cr | -₹1 Cr | ₹5 Cr | ₹2 Cr | -₹1 Cr | ₹2 Cr | ₹64 L |
| ₹6 Cr | ₹12 Cr | ₹13 Cr | ₹25 Cr | ₹21 Cr | ₹24 Cr | ₹41 Cr | ₹12 Cr | ₹11 Cr | ₹5 Cr | ₹6 Cr | ₹82 L | ₹2 Cr | ₹3 Cr | ₹1 Cr | ₹96 L |
| -₹42 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹69 L | ₹3 L | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| -₹15 Cr | -₹51 L | ₹16 L | ₹5 L | -₹18 L | -₹4 Cr | ₹2 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹68,842 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹3 Cr | ₹6 Cr | ₹12 Cr | ₹13 Cr | ₹25 Cr | ₹21 Cr | ₹24 Cr | ₹41 Cr | ₹12 Cr | ₹11 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Hester Biosciences Share Price
2329.90+0.00 (-0.94%)
+39.36% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 3 out of 9 oscillators
RSI
55.19Buy
STOCH %K
26.57Neutral
MACD Level(12,26)
34.58Buy
Ultimate Oscillator
42.09Sell
Aroon Oscillator
16.00Sell
BOP
-0.20Sell
CCI
59.04Neutral
Williams %R
-73.43Neutral
Momentum
51.20Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 8
Bearish signals: 1 out of 9 moving averages
EMA 9
2330.24Sell
SMA 9
2329.80Buy
EMA 21
2298.68Buy
SMA 21
2289.20Buy
EMA 50
2264.64Buy
SMA 50
2226.83Buy
EMA 200
2087.06Buy
SMA 200
1981.65Buy
WMA 20
2327.66Buy
Pivot
Pivot
Classic
Resistance 5
2748.37
Resistance 4
2653.37
Resistance 3
2558.37
Resistance 2
2463.37
Resistance 1
2407.73
Pivot
2368.37
Support 1
2312.73
Support 2
2273.37
Support 3
2178.37
Support 4
2083.37
Support 5
1988.37
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Hester Biosciences Share Price
2329.90+0.00 (-0.94%)
+39.36% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 44.28% | 53.73% | 53.73% | 53.73% | 53.73% | 53.73% |
| 0.30% | 0.31% | 0.38% | 0.52% | 0.53% | 0.51% |
| 0.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 55.34% | 45.96% | 45.89% | 45.75% | 45.74% | 45.76% |
Bulk & block deals
Name
Rajiv Dinesh Gandhi
Hester Coatings Private Limited
Rajiv Dinesh Gandhi
Hester Coatings Private Limited
K Pal Joy
Shirin Dhunjishaw Ghandhi
Piyush Batukbhai Dave
Piyush Batukbhai Dave
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 22 Mar 2017 | Purchase | 6.59 Cr | ₹732.10 | 90 K | Bulk | 1.057965 | BSE |
| 22 Mar 2017 | Sell | 6.59 Cr | ₹732.10 | 90 K | Bulk | 1.057965 | BSE |
| 22 Mar 2017 | Purchase | 6.59 Cr | ₹732.10 | 90 K | Block | 1.057965 | BSE |
| 22 Mar 2017 | Sell | 6.59 Cr | ₹732.10 | 90 K | Block | 1.057965 | BSE |
| 21 Aug 2014 | Sell | 1.32 Cr | ₹276 | 47.80 K | Bulk | 0.561897 | BSE |
| 01 Jul 2014 | Sell | 1.03 Cr | ₹171.80 | 60 K | Bulk | 0.70531 | BSE |
| 24 Jun 2013 | Sell | 55.34 L | ₹110.67 | 50 K | Bulk | 0.587758 | BSE |
| 24 Jun 2013 | Purchase | 55.12 L | ₹110.23 | 50 K | Bulk | 0.587758 | BSE |
Insider trading & SAST
Client name
Dr. Bhupendra Vithaldas Gandhi
Rajiv Dinesh Gandhi & Pacs
Bhupendra Vithaldas Gandhi
Rajiv Dinesh Gandhi
Oaklane Capital Management Llp
Shaila Bhupendra Gandhi & Pacs
Bhupendra Vittaldas Gandhi Huf & Pacs
Bhupendra Vithaldas Gandhi Huf
Shaila Bhupendra Gandhi
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 06 Oct 2025 | Promoter | Disposal | 0.01 | 53.73 | 0 | — | 1.11 K | 04 Sep 2025 | Inter-se Transfer / Gift | 45,70,944 | SAST | 29(2) | — |
| 06 Oct 2025 | Promoter | Acquisition | 0.01 | 53.73 | 0 | — | 1.11 K | 04 Sep 2025 | Inter-se Transfer | 45,70,944 | SAST | 29(2) | — |
| 05 Sep 2025 | Promoter & Director | Disposal | 0.01306 | 4.68 | 0 | — | 1.11 K | 04 Sep 2025 | Gift | 3,97,989 | Insider Trading | — | Equity Shares |
| 05 Sep 2025 | Promoter & Director | Acquisition | 0.01306 | 10.48 | 0 | — | 1.11 K | 04 Sep 2025 | Gift | 8,91,508 | Insider Trading | — | Equity Shares |
| 31 Jan 2024 | Other | Acquisition | 0.12 | 5.06 | 0 | — | 10 K | 29 Jan 2024 | Market | 4,30,203 | SAST | 29(1) | — |
| 10 Feb 2023 | Promoter | Acquisition | 3.55 | 53.73 | 0 | — | 3.02 L | 06 Feb 2023 | Inter-se Transfer | 45,70,944 | SAST | 29(2) | — |
| 09 Feb 2023 | Promoter | Disposal | 3.55 | 53.73 | 0 | — | 3.02 L | 06 Feb 2023 | Off Market / Inter se transfer | 45,70,944 | SAST | 29(2) | — |
| 08 Feb 2023 | Promoter | Disposal | 3.545316 | 0 | 0 | — | 3.02 L | 06 Feb 2023 | Others | 0 | Insider Trading | — | Equity Shares |
| 08 Feb 2023 | Promoter | Acquisition | 3.545316 | 5.78 | 0 | — | 3.02 L | 06 Feb 2023 | Others | 4,91,300 | Insider Trading | — | Equity Shares |
Hester Biosciences Share Price
2329.90+0.00 (-0.94%)
+39.36% past 1 Year
Hester Biosciences Limited (Hester) is the largest poultry vaccine manufacturer and one of the leading animal healthcare companies in India. Incorporated in 1987 the company has come a long way
Corporate Actions
Date
Type
Details
Company details
Hester Biosciences Share Price
2329.90+0.00 (-0.94%)
+39.36% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Hester Biosciences Share Price
2329.90+0.00 (-0.94%)
+39.36% past 1 Year
News
1 of 20
ResultHESTERBIO5 Nov 2026
Hester Biosciences reported second-quarter EBITDA of Rs 32.70 crores, rising from Rs 11.70 crores in the corresponding year-ago quarter. EBITDA margin expanded to 33.4% from 16.48% year on year, indicating a substantial improvement in operating profitability. Revenue and PAT figures, sequential performance, analyst estimates, management commentary, and market reaction were not provided in the available update.
Hester Biosciences Reports Strong Second Quarter Revenue Growth Year On Year
ResultHESTERBIO5 Nov 2026
Hester Biosciences reported Q2 revenue of Rs 97.90 crores, compared with Rs 71.00 crores in the corresponding quarter a year earlier, representing year on year growth of approximately 37.89%. The update indicates improved quarterly operating scale for the animal healthcare and pharmaceutical formulations company.
EBITDA, PAT, operating margin, net margin, quarter on quarter comparison, analyst estimates, management commentary and market reaction were not provided in the available information. Accordingly, no additional profitability or guidance data has been included.
Hester Biosciences operates in the animal healthcare and pharmaceuticals segment and is listed on NSE under the symbol HESTERBIO and on BSE under code 524669.
Hester Biosciences Reports Stronger Second Quarter Consolidated Profit
ResultHESTERBIO5 Nov 2026
Hester Biosciences reported consolidated net profit of Rs 20.40 crores for the second quarter, compared with Rs 14.50 crores in the corresponding quarter of the previous year, representing a year-on-year increase of 40.69%. Revenue, EBITDA, operating margin, net margin, and quarter-on-quarter comparisons were not provided in the available information and are therefore not included. The profit growth indicates improved earnings performance during the reported period. No management guidance, analyst consensus comparison, or market reaction was provided.
Hester Biosciences reports Profit after tax of 16.66 Crores, in the September 2026 quarter
ResultHESTERBIO5 Nov 2026
NULL
Hester Biosciences Approves Renewable Energy Investment In Slyce Agri World
Stock NewsHESTERBIO6 Oct 2026
Hester Biosciences has approved an investment of up to Rs 1.05 crores in Slyce Agri World LLP for renewable energy initiatives. The investment will represent 26% of the LLP's total fixed capital.
The transaction expands Hester Biosciences' participation into renewable energy infrastructure, although the available announcement does not specify the project's capacity, expected returns, funding structure, or implementation timeline. The investment amount is not material enough on the available information to indicate a significant immediate effect on the company's earnings, leverage, or market share.
Hester Biosciences reports steady Q1 EBITDA with higher margin
ResultHESTERBIO30 Jul 2026
Hester Biosciences reported Q1 EBITDA of Rs 22.80 crores, unchanged from Rs 22.80 crores a year earlier. EBITDA margin improved to 29.5% from 27.0% in the same period last year, indicating better operating efficiency.
The update provided only EBITDA and margin details, with revenue and PAT not disclosed in the supplied context. No QoQ figures, consensus estimates, or management guidance were included. Based on the available numbers, the quarter appears operationally stable, with margin expansion being the main highlight.
Hester Biosciences Q1 consolidated profit before tax declines year-on-year
ResultHESTERBIO30 Jul 2026
Hester Biosciences has reported its consolidated financial performance for the first quarter, with a noticeable decline in profitability on a profit before tax basis compared to the same period last year. The company’s Q1 consolidated profit before tax stood at Rs 16.30 crores, against Rs 20.10 crores in the corresponding quarter of the previous year, indicating a year-on-year reduction in pre-tax earnings. This suggests pressure on the company’s operating or non-operating performance at the pre-tax level, even though detailed revenue, EBITDA, and net profit figures are not provided in the available context.
The results also include a significant exceptional item of Rs 85.30 crores. Exceptional items typically represent one-off, non-recurring gains or losses arising from events such as asset sales, impairments, restructuring charges, or legal settlements. The presence of such a large exceptional item implies that the reported profitability at the net level could be materially different from the underlying operating performance, depending on whether this item is a gain or a loss. However, in the absence of specific disclosure on the nature and direction of this exceptional item, its exact impact on net profit, margins, and overall financial health cannot be quantified from the given information.
Key metrics such as revenue growth, EBITDA, operating margin, net margin, and management commentary or guidance are not available in the provided context, and no comparison with street expectations or consensus estimates is mentioned. Likewise, there is no data on how the stock reacted to these numbers in terms of price movement on NSE or BSE. Based solely on the disclosed figures, the quarter reflects weaker pre-tax performance year-on-year, moderated or amplified by a large exceptional item, leaving the underlying trend in core operations indeterminate without further financial details.
Hester Biosciences reports strong YoY jump in Q1 consolidated net profit
ResultHESTERBIO30 Jul 2026
Hester Biosciences has reported a sharp improvement in profitability for the latest reported quarter, with Q1 consolidated net profit coming in at Rs 97.00 crores compared with Rs 16.40 crores in the corresponding quarter last year. This represents a substantial year-on-year increase in profit after tax, indicating a markedly stronger earnings performance versus the previous period. The news highlights a significant expansion in bottom-line performance on a consolidated basis, which may reflect improved operational efficiency, better product mix, or favourable market conditions for the company’s portfolio in animal healthcare and vaccines. However, the available context only specifies net profit figures and does not provide details on consolidated revenue, EBITDA, or margin metrics for the quarter, nor does it offer quarter-on-quarter comparisons.
In the absence of disclosed revenue and EBITDA numbers, as well as operating or net margin trends, the focus of this update remains on the pronounced growth in consolidated net profit. The information provided also does not include street expectations or consensus estimates, so it is not possible to quantitatively assess whether these earnings are above or below market forecasts. No management commentary, forward-looking guidance, or segmental performance breakdown has been mentioned in the given context, and there is no data on immediate market reaction in terms of share price movement on NSE or BSE following the announcement. Nevertheless, such a strong year-on-year increase in consolidated net profit is typically viewed as a positive earnings development for equity investors tracking Hester Biosciences, especially in the context of routine quarterly corporate results where profit growth is a key performance indicator.
Hester Biosciences exits Texas Lifesciences with final 11% stake sale
Stock NewsHESTERBIO9 Jul 2026
Hester Biosciences has sold its remaining 11% stake in Texas Lifesciences Private Limited for Rs 2.3 crore, completing its full exit from the company. The transaction follows the earlier approved plan to divest 43.81% of its holding in Texas Lifesciences from an initial 54.81% stake, after which the subsidiary status would cease.
According to the reported terms, the stake was transferred to Ticop Life Private Limited, an entity linked to the existing promoter shareholders of Texas Lifesciences. Hester Biosciences will no longer hold any equity in Texas Lifesciences after this sale, and the move is aimed at simplifying the group structure while allowing the company to continue business dealings with the entity.
The development is a routine corporate restructuring event with limited immediate financial impact, as the stake being sold is small and the transaction size is modest relative to the company’s scale.
Hester Biosciences submits secretarial compliance report
Stock NewsHESTERBIO18 May 2026
NULL
Hester Biosciences informs about newspaper publication
Stock NewsHESTERBIO18 May 2026
NULL
Hester Biosciences informs about transcript of conference call
Stock NewsHESTERBIO18 May 2026
NULL
Hester Biosciences - Quaterly Results
ResultHESTERBIO15 May 2026
NULL
Hester Biosciences board recommends dividend of Rs 11 per equity share
Stock NewsHESTERBIO15 May 2026
Hester Biosciences has announced that its board has recommended a dividend of Rs 11 per equity share. The announcement reflects the company’s decision to share profits with shareholders through a cash payout for the financial year, subject to requisite shareholder approval at the upcoming annual general meeting. The quantum of Rs 11 per share indicates a meaningful cash return, though the exact dividend yield and payout ratio cannot be assessed without the prevailing market price and earnings data. Nevertheless, the move signals management’s confidence in the company’s earnings visibility and cash flow generation.
From an equity perspective, a consistent or enhanced dividend recommendation can support investor perception of stability, particularly for income-focused investors and long-term shareholders. For Hester Biosciences, which operates in the animal healthcare and vaccine space, such a payout suggests that the balance sheet and operating cash flows are strong enough to accommodate shareholder distributions alongside ongoing business requirements. The dividend decision may also help in anchoring the stock during periods of volatility, as regular cash returns can be seen as a partial hedge against price fluctuations.
However, without additional disclosures on earnings growth, capex plans, or leverage, it is not possible to fully quantify the long-term impact on retained earnings and reinvestment capacity. The market reaction will likely depend on how this dividend compares with historical payouts and current street expectations. In the absence of explicit information on these factors, the development can be viewed primarily as a routine yet positive corporate action that rewards existing shareholders.
Hester Biosciences reports Profit after tax of 26.38 Crores, in the March 2026 quarter
ResultHESTERBIO15 May 2026
NULL
Hester Biosciences posts strong year-on-year revenue growth in Q4 FY26 results
ResultHESTERBIO15 May 2026
Hester Biosciences reported a healthy increase in standalone revenue for the fourth quarter, with topline rising to about Rs 100 crores from roughly Rs 81.90 crores on a year-on-year basis. This indicates a solid double-digit growth in sales, reflecting improved demand or better realisation in its operating segments. The sharp expansion in revenue underscores positive business momentum compared to the same quarter last year, suggesting that the company may be benefiting from stronger product offtake, new launches, better geographic reach, or a favourable pricing environment in its core markets.
Key profitability metrics such as EBITDA, profit after tax, and margin profile have not been disclosed in the available context, so it is not possible to draw firm conclusions about cost control, operating leverage, or net profitability trends. Similarly, there is no visibility on quarter-on-quarter performance, management guidance, or how the reported numbers compare with consensus expectations, if any. In the absence of this information, the revenue print alone signals operational traction but does not fully capture the quality or sustainability of earnings. Market reaction, including stock price movement, trading volumes, or changes in analyst stance following the result, is not available in the provided data, and therefore cannot be assessed. Overall, the reported Q4 revenue growth versus the prior-year quarter marks a positive development for Hester Biosciences’ topline trajectory, though a complete earnings assessment would require additional details on margins, profitability, and forward-looking commentary.
Hester Biosciences Q4 EBITDA and margin expand sharply on strong operating performance
ResultHESTERBIO15 May 2026
Hester Biosciences has reported a strong improvement in operating performance for the fourth quarter, led by a sharp jump in EBITDA and operating margins on a year-on-year basis. Q4 EBITDA came in at Rs 36.10 crores compared with Rs 13.50 crores in the corresponding quarter last year, indicating a substantial increase in operating profitability in absolute terms.
The company’s Q4 EBITDA margin expanded to 36 percent versus 17 percent a year ago. This near doubling of the margin suggests better operating leverage, improved product mix, and/or tighter cost control compared with the prior-year period. The data highlights a pronounced turnaround at the operating level, with each rupee of revenue now generating significantly higher operating profit than in the same quarter of the previous financial year.
The available information focuses solely on EBITDA and EBITDA margin; revenue, PAT, and quarter-on-quarter comparisons are not disclosed in the provided context. There is also no reference to street expectations or consensus estimates, nor any explicit management guidance or commentary in the current data set. As such, the assessment of performance is based primarily on the strong expansion in operating profit and margins on a year-on-year basis.
In the absence of additional financial metrics, the reported numbers still indicate a significantly stronger operating performance for Hester Biosciences versus the same quarter last year, which is typically viewed constructively by market participants tracking profitability trends in the company.
Hester Biosciences Q4 standalone net profit rises to Rs 16 crores
ResultHESTERBIO15 May 2026
Hester Biosciences reported a standalone net profit of Rs 16 crores for the fourth quarter, compared with Rs 1.30 crores in the same period last year. The update provided only net profit figures and did not include revenue, EBITDA, margin data, or quarter-on-quarter comparison.
Based on the available information, the company delivered a sharp year-on-year improvement in profitability for the quarter. No management commentary, guidance, or stock market reaction was provided in the context. Since the release is limited to the bottom-line figure, the broader operating performance cannot be assessed from the given text alone.
Hester Biosciences informs about compliance certificate
Stock NewsHESTERBIO8 Apr 2026
NULL
Hester Biosciences gets nod to divest 43.81% stake in Texas Lifesciences
Stock NewsHESTERBIO11 Mar 2026
The transaction is expected to be completed within three months

